Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

MMPOWER — elamipretide (SS-31) in primary mitochondrial myopathy

The clinical programme for the mitochondria-targeting tetrapeptide elamipretide. The Institute records the phase 3 result as a negative result and treats the programme as informative for that reason.

The clinical programme for the mitochondria-targeting tetrapeptide elamipretide. The Institute records the phase 3 result as a negative result and treats the programme as informative for that reason.

Sponsor class: Manufacturer-sponsored. First record: 2014.

Showing 0 records on this page

Records in this programme

9 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
MMPOWER-2SS-31 (elamipretide)Phase 2ReportedRandomised crossover302018Moderate
MMPOWER-3SS-31 (elamipretide)Phase 3ReportedRandomised, double-blind, placebo-controlled2182022Moderate
MMPOWER-2-ADHERENCEprogramme recordSS-31 (elamipretide)Phase 2ReportedObservational—2018Very low
MMPOWER-2-BIOMARKERprogramme recordSS-31 (elamipretide)Phase 2ReportedRandomised, double-blind, placebo-controlled—2018Very low
MMPOWER-2-ELDERLYprogramme recordSS-31 (elamipretide)Phase 2ReportedRandomised, double-blind, placebo-controlled—2018Very low
MMPOWER-2-OLEprogramme recordSS-31 (elamipretide)Phase 2ReportedSingle-arm open-label—2018Very low
MMPOWER-3-ADHERENCEprogramme recordSS-31 (elamipretide)Phase 3ReportedObservational—2022Very low
MMPOWER-3-BIOMARKERprogramme recordSS-31 (elamipretide)Phase 3ReportedRandomised, double-blind, placebo-controlled—2022Very low
MMPOWER-3-OLEprogramme recordSS-31 (elamipretide)Phase 3ReportedSingle-arm open-label—2022Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.